Investor Relations

Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers.

Esperion Therapeutics is a publicly traded company (since 2013) and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Esperion Therapeutics (NASDAQ: ESPR) 11:52 AM ET on Apr 24, 2014
Last Price Change Open Day High 52-Week High
14.53
0.15  down   (1.022%) 14.81 14.87 20.10
Volume Previous Close Day Low 52-Week Low
12,600 14.68 14.05 10.90

View all »   RSSRecent Releases

Mar 24, 2014
Esperion Therapeutics to Present at BioCentury Future Leaders in the Biotech Industry Conference

Mar 5, 2014
Esperion Therapeutics Provides ETC-1002 Program Update; Reports Fourth Quarter and Full Year 2013 Financial Results